var data={"title":"Fluorescein: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fluorescein: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6212?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fluorescein-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fluorescein: Pediatric drug information&quot;</a> and <a href=\"topic.htm?path=fluorescein-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fluorescein: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172390\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>AK-Fluor;</li>\n      <li>Bio Glo;</li>\n      <li>Fluor-I-Strips A.T.;</li>\n      <li>Fluorescite;</li>\n      <li>Ful-Glo</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172391\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Fluorescite</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172419\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Diagnostic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172392\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Diagnostic staining:</b> Ophthalmic: Strips: Moisten strip with sterile water, saline or ophthalmic fluid. Touch conjunctiva or fornix with tip of strip until adequately stained.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ophthalmic angiography/angioscopy:</b> <b>Note:</b> Prior to injection, an intradermal test dose of 0.05 mL may be used if an allergy is suspected. Evaluate 30-60 minutes following intradermal injection. A negative skin test does not exclude the potential for a reaction to occur. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: 500 mg as a single dose into antecubital vein; a dose of 200 mg may be appropriate in cases when a highly sensitive imaging system (eg, scanning laser ophthalmoscope) is used.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral (off-label route): 1 g of injection solution has been administered orally; clarity of photographs, particularly during early arterial phase, is reportedly poorer than photographs obtained following IV administration (Hara, 1998)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172404\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=fluorescein-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fluorescein: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Diagnostic staining:</b> Children and Adolescents: Ophthalmic: Strips: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ophthalmic angiography/angioscopy:</b> Children and Adolescents: <b>Note:</b> Prior to injection, an intradermal test dose of 0.05 mL may be used if an allergy is suspected. Evaluate 30-60 minutes following intradermal injection. A negative skin test does not exclude the potential for a reaction to occur. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: 7.7 mg/kg as a single dose into antecubital vein; maximum dose: 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172393\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5095158\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15405178\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustment provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172384\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AK-Fluor: 10% (5 mL); 25% (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fluorescite: 10% (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Strip, Ophthalmic, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bio Glo: 1 mg (100 ea, 300 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fluor-I-Strips A.T.: 1 mg (300 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ful-Glo: 0.6 mg (300 ea); 1 mg (100 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172373\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5095179\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Inject into the antecubital vein at a rate of ~1 mL/second using a 23-gauge butterfly needle attached to a small syringe. Prior to turning off room light, ensure extravasation has not occurred. Immediate treatment for anaphylaxis (including epinephrine) should be available or a test dose may be advised in some patients. Do not mix or dilute with other solutions or drugs; flush IV cannulas before and after drugs are administered. Luminescence usually appears in the retina and choroidal vessels in 7 to 14 seconds. Maintain venous access following procedure in the event treatment is needed for anaphylaxis. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral (off-label route): The solution for injection has been administered orally in certain patients. Four grams of sugar or 1 teaspoonful of artificial sweetener may be added to decrease the bitterness of the solution. Luminescence appears in 10 to 15 minutes following oral administration (Hara 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Strips: Fluorescein impregnated tip should be moistened prior to application. Strip should be applied to conjunctiva or fornix. For best results, patient should blink several times after application.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172385\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ophthalmic angiography/angioscopy (injection):</b> Diagnostic aid in ophthalmic angiography or angioscopy of the retina and iris vasculature</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ophthalmic diagnostic staining (strips):</b> To stain the anterior segment of the eye for procedures (such as fitting contact lenses), disclosing corneal injury, and in applanation tonometry</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172379\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Reactions associated with use of the injection. Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Arterial ischemia (basilar; rare), hypotension, shock, syncope</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Convulsions (rare), dizziness (Kwan 2006), headache, nerve palsy (localized; [Kwan 2006]), seizure (rare; [Kwan 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, rash at injection site, skin discoloration (yellow), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Dysgeusia, gastrointestinal distress, nausea (common), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urine discoloration (bright yellow)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Hemolytic anemia (Kwan 2006), sickle cell disease (Kwan 2006, Acheson 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Extravasation, inflammation at injection site</p>\n    <p style=\"text-indent:0em;\">Respiratory: Bronchospasm, pulmonary edema (acute; [Kwan 2006])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172387\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to fluorescein or any other component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172377\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions may occur (death has been reported rarely); immediate treatment (including epinephrine) should be available. Serious intolerance reactions may be induced; history of adverse reaction to fluorescein or allergic reaction to foods or drugs, such as urticaria, asthma, eczema, or allergic rhinitis, may increase risk. Premedicating some patients (eg, antihistamines, corticosteroids) may be advisable. An intradermal skin test may be performed prior to use when allergy is suspected; however, a negative skin test does not rule out the potential for a reaction to occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastrointestinal effects: Nausea and/or vomiting and gastrointestinal distress occur commonly within the first few minutes following injection; these reactions usually subside within 10 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skin/urine discoloration: Following use of the injection, skin may temporarily turn a yellow color within a few minutes of administration and usually fades in 6 to 12 hours. Urine may appear bright yellow for 24 to 36 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Allergies/asthma: Respiratory reactions may occur, especially in patients with a history of allergies or bronchial asthma; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Contact lens wearers: Ophthalmic products should not be used in patients with soft contact lenses, will cause them to discolor. Flush eyes with saline following use and wait at least 1hour prior to replacing contact lenses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Injection: For administration via antecubital vein only; not for intrathecal or arterial injection. Avoid extravasation; severe local tissue damage may result, including skin sloughing, superficial phlebitis, subcutaneous granuloma, and toxic neuritis along the median curve in the antecubital area. Following extravasation, severe pain may last up to several hours. Discontinue immediately if extravasation occurs.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299351\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220438\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8461&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172380\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5095147\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Pregnancy outcome information is available following fluorescein use in pregnant women (Halperin 1990; Olk 1991).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5095150\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Fluorescein is excreted into breast milk when administered by injection (Maquire 1988) and ophthalmic drops (Mattern 1990). Measurable concentrations can be detected for at least 4 days following injection; pumping and discarding milk during this time period is recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5095183\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Injection: Hypersensitivity reactions (during procedure and after)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172376\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Fluorescein sodium, a fluoresce dye, responds to wavelengths between 465-490 nm of electromagnetic radiation and light, and fluoresces at wavelengths of 520-530 nm.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15405175\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 0.5 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Rapidly metabolized to fluorescein monoglucuronide (~80% is metabolized 1 hour following IV administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine; systemic clearance essentially complete 48 to 72 hours after dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323157\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Fluorescite Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (5 mL): $55.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Strip</b> (Bio Glo Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $14.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Strip</b> (Fluor-I-Strips A.T. Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (300): $77.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Strip</b> (Ful-Glo Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg (300): $36.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $14.25</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172388\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aka-Fluor (PE);</li>\n      <li>Cendo Fluorescein (ID);</li>\n      <li>Colircusi Fluoresceina (ES);</li>\n      <li>Fluocyne (FR);</li>\n      <li>Fluoftal (AT);</li>\n      <li>Fluor-I-Strip (NL);</li>\n      <li>Fluoralfa (IT);</li>\n      <li>Fluore Stain Strips (IN);</li>\n      <li>Fluorescein (DE, HR);</li>\n      <li>Fluoresceina (BR);</li>\n      <li>Fluoresceina Oculos (ES);</li>\n      <li>Fluoresceine (IL, LU);</li>\n      <li>Fluoresceine Ophtadose (BE);</li>\n      <li>Fluoresceine SDU Faure (CH);</li>\n      <li>Fluoresceinnatrium (SE);</li>\n      <li>Fluorescite (AE, AR, AU, BF, BH, BJ, CI, CN, CY, CZ, EC, EE, EG, ET, GH, GM, GN, HK, HN, IL, IQ, IR, JO, KE, KR, KW, LB, LR, LV, LY, MA, ML, MR, MU, MW, MY, NE, NG, NZ, OM, PL, QA, SA, SC, SD, SG, SL, SN, SY, TH, TN, TR, TW, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Fluorets (AE, GB, HK, MT, MY, QA, SA);</li>\n      <li>Flurocin (BD);</li>\n      <li>Flyuurestsyt (UA);</li>\n      <li>Minims Fluorescein Sodium (FI, GB);</li>\n      <li>Minims Fluoresceine (BE);</li>\n      <li>Ophth-fluorstrip (PK);</li>\n      <li>Optifluor Diba (MX);</li>\n      <li>Retinofluor (AU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    AK-Fluor (fluorescein injection 10% and 25%) [prescribing information]. Lake Forest, IL: Akorn Inc; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fluorescite (fluorescein injection 10%) [prescribing information]. Fort Worth, Texas: Alcon Laboratories, Inc; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halperin LS, Olk RJ, Soubrane G, Coscas G. Safety of fluorescein angiography during pregnancy. <i>Am J Ophthalmol</i>. 1990;109(5):563-566.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorescein-drug-information/abstract-text/1970705/pubmed\" target=\"_blank\" id=\"1970705\">1970705</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hara T, Inami M, and Hara T. &ldquo;Efficacy and Safety of Fluorescein Angiography With Orally Administered Sodium Fluorescein,&rdquo; <i>Am J Ophthalmol</i>, 1998, 126(4):560-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorescein-drug-information/abstract-text/9780101/pubmed\" target=\"_blank\" id=\"9780101\">9780101</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kwan AS, Barry C, McAllister IL, et al, &ldquo;Fluorescein Angiography and Adverse Drug Reactions Revisited: The Lions Eye Experience,&rdquo; <i>Clin Experiment Ophthalmol</i>, 2006, 34(1):33-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorescein-drug-information/abstract-text/16451256/pubmed\" target=\"_blank\" id=\"16451256\">16451256</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maquire AM, Bennett J. Fluorescein elimination in human breast milk. <i>Arch Ophthalmol</i>. 1988;106(6):718-719.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorescein-drug-information/abstract-text/3369981/pubmed\" target=\"_blank\" id=\"3369981\">3369981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mattern J, Mayer PR. Excretion of fluorescein into breast milk. <i>Am J Ophthalmol</i>. 1990;109(5):598-599.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorescein-drug-information/abstract-text/2333925/pubmed\" target=\"_blank\" id=\"2333925\">2333925</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Olk RJ, Halperin LS, Soubrane G, Coscas G. Fluorescein angiography--is it safe to use in a pregnant patient? <i>Eur J Ophthalmol</i>. 1991;1(2):103-106.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluorescein-drug-information/abstract-text/1821200/pubmed\" target=\"_blank\" id=\"1821200\">1821200</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8461 Version 112.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F172390\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F172391\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F172419\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F172392\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F172404\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F172393\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F5095158\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15405178\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F172384\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F172373\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F5095179\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F172385\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F172379\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F172387\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F172377\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299351\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220438\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F172380\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5095147\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5095150\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5095183\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F172376\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F15405175\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323157\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F172388\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8461|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fluorescein-patient-drug-information\" class=\"drug drug_patient\">Fluorescein: Patient drug information</a></li><li><a href=\"topic.htm?path=fluorescein-pediatric-drug-information\" class=\"drug drug_pediatric\">Fluorescein: Pediatric drug information</a></li></ul></div></div>","javascript":null}